AHRQ (Agency for Healthcare Research and Quality). 2013. A framework for measuring integration of behavioral health and primary care. https://integrationacademy.ahrq.gov/products/ibhc-measures-atlas/framework-measuring-integration-behavioral-health-and-primary-care (accessed March 15, 2020).
Amaro, H., M. Chernoff, V. Brown, S. Arévalo, and M. Gatz. 2007a. Does integrated trauma-informed substance abuse treatment increase treatment retention? Journal of Community Psychology 35(7):845–862.
Amaro, H., J. Dai, S. Arévalo, A. Acevedo, A. Matsumoto, R. Nieves, and G. Prado. 2007b. Effects of integrated trauma treatment on outcomes in a racially/ethnically diverse sample of women in urban community-based substance abuse treatment. Journal of Urban Health 84(4):508–522.
Andrilla, C. H. A., T. E. Moore, D. G. Patterson, and E. H. Larson. 2019. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health 35(1):108–112.
Ashford, R. D., B. Curtis, and A. M. Brown. 2018. Peer-delivered harm reduction and recovery support services: Initial evaluation from a hybrid recovery community drop-in center and syringe exchange program. Harm Reduction Journal 15(1).
Aspinall, E. J., D. Nambiar, D. J. Goldberg, M. Hickman, A. Weir, E. Van Velzen, N. Palmateer, J. S. Doyle, M. E. Hellard, and S. J. Hutchinson. 2014. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: A systematic review and meta-analysis. International Journal of Epidemiology 43(1):235–248.
Bach, P., and D. Hartung. 2019. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addiction Science & Clinical Practice 14(1):30.
Balio, C. P., K. K. Wiley, Jr., M. S. Greene, and J. R. Vest. 2020. Opioid-related emergency department encounters: Patient, encounter, and community characteristics associated with repeated encounters. Annals of Emergency Medicine 75(5):568–575.
Blevins, C. E., N. Rawat, and M. D. Stein. 2018. Gaps in the substance use disorder treatment referral process: Provider perceptions. Journal of Addiction Medicine 12(4):273.
Carroll, J. J., J. D. Rich, and T. C. Green. 2018. Reducing collateral damage in responses to the opioid crisis. American Journal of Public Health 108(3):349–350.
CDC (Centers for Disease Control and Prevention). 2018. New data show growing complexity of drug overdose deaths in America. https://www.cdc.gov/media/releases/2018/p1221-complexity-drug-overdose.html (accessed March 2, 2020).
CDC. 2019. Other drugs. https://www.cdc.gov/drugoverdose/data/otherdrugs.html (accessed March 2, 2020).
CDC. 2020. Synthetic opioid overdose data. https://www.cdc.gov/drugoverdose/data/fentanyl.html (accessed March 2, 2020).
Dasgupta, N., L. Beletsky, and D. Ciccarone. 2018. Opioid crisis: No easy fix to its social and economic determinants. American Journal of Public Health 108(2):182–186.
Davis, C. S., S. Ruiz, P. Glynn, G. Picariello, and A. Y. Walley. 2014. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. American Journal of Public Health 104(8):e7–e9.
Englander, H., J. Gregg, J. Gullickson, O. Cochran-Dumas, C. Colasurdo, J. Alla, D. Collins, and C. Nicolaidis. 2019. Recommendations for integrating peer mentors in hospital-based addiction care. Substance Abuse 1–6.
Fairbairn, N., P. O. Coffin, and A. Y. Walley. 2017. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. International Journal of Drug Policy 46:172–179.
Giglio, R. E., G. Li, and C. J. DiMaggio. 2015. Effectiveness of bystander naloxone administration and overdose education programs: A meta-analysis. Injury Epidemiology 2(1):10.
Goddard, P. 2003. Changing attitudes towards harm reduction among treatment professionals: A report from the American Midwest. International Journal of Drug Policy 14(3):257–260.
Goldman, J. E., K. M. Waye, K. A. Periera, M. S. Krieger, J. L. Yedinak, and B. D. Marshall. 2019. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: A qualitative study. Harm Reduction Journal 16(1):3.
Gossop, M., D. Stewart, N. Browne, and J. Marsden. 2002. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: Protective effect of coping responses. Addiction 97(10):1259–1267.
Gostin, L. O., J. G. Hodge, and S. A. Noe. 2017. Reframing the opioid epidemic as a national emergency. JAMA 318(16):1539–1540.
Green, T. C., J. Clarke, L. Brinkley-Rubinstein, B. D. Marshall, N. Alexander-Scott, R. Boss, and J. D. Rich. 2018. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry 75(4):405–407.
Groshkova, T., D. Best, and W. White. 2013. The assessment of recovery capital: Properties and psychometrics of a measure of addiction recovery strengths. Drug and Alcohol Review 32(2):187–194.
Guerrero, E. G., J. C. Marsh, T. Khachikian, H. Amaro, and W. A. Vega. 2013. Disparities in Latino substance use, service use, and treatment: Implications for culturally and evidence-based interventions under health care reform. Drug and Alcohol Dependence 133(3):805–813.
Guerrero, E. G., G. A. Aarons, C. E. Grella, B. R. Garner, B. Cook, and W. A. Vega. 2016. Program capacity to eliminate outcome disparities in addiction health services. Administration and Policy in Mental Health and Mental Health Services Research 43(1):23–35.
Guerrero, E., K. Fenwick, Y. Kong, and H. Amaro. 2017a. Racial, ethnic and gender disparities in substance use at discharge. Drug and Alcohol Dependence 100(171):e79.
Guerrero, E. G., B. R. Garner, B. Cook, Y. Kong, W. A. Vega, and L. Gelberg. 2017b. Identifying and reducing disparities in successful addiction treatment completion: Testing the role of medicaid payment acceptance. Substance Abuse Treatment, Prevention, and Policy 12(1):27.
Guy, Jr., G. P., T. M. Haegerich, M. E. Evans, J. L. Losby, R. Young, and C. M. Jones. 2019. Vital signs: Pharmacy-based naloxone dispensing—United States, 2012–2018. Morbidity and Mortality Weekly Report 68(31):679.
Heath, B., P. Wise Romero, and K. Reynolds. 2013. A standard framework for levels of integrated healthcare. Washington, DC: SAMHSA-HRSA Center for Integrated Health Solutions.
Jones, J. D., S. Mogali, and S. D. Comer. 2012. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug and Alcohol Dependence 125(1–2):8–18.
Kerensky, T., and A. Y. Walley. 2017. Opioid overdose prevention and naloxone rescue kits: What we know and what we don’t know. Addiction Science & Clinical Practice 12(1):4.
Koester, S., S. R. Mueller, L. Raville, S. Langegger, and I. A. Binswanger. 2017. Why are some people who have received overdose education and naloxone reticent to call emergency medical services in the event of overdose? International Journal of Drug Policy 48:115–124.
Krieger, M. S., W. C. Goedel, J. A. Buxton, M. Lysyshyn, E. Bernstein, S. G. Sherman, J. D. Rich, S. E. Hadland, T. C. Green, and B. D. Marshall. 2018a. Use of rapid fentanyl test strips among young adults who use drugs. International Journal of Drug Policy 61:52–58.
Krieger, M. S., J. L. Yedinak, J. A. Buxton, M. Lysyshyn, E. Bernstein, J. D. Rich, T. C. Green, S. E. Hadland, and B. D. Marshall. 2018b. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduction Journal 15(1):7.
Legerski, J.-P., and S. L. Bunnell. 2010. The risks, benefits, and ethics of trauma-focused research participation. Ethics & Behavior 20(6):429–442.
McCauley, J. L., T. Killeen, D. F. Gros, K. T. Brady, and S. E. Back. 2012. Posttraumatic stress disorder and co-occurring substance use disorders: Advances in assessment and treatment. Clinical Psychology: Science and Practice 19(3):283–304.
NASEM (National Academies of Sciences, Engineering, and Medicine). 2017. Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: The National Academies Press.
NASEM. 2019. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press.
NASEM. 2020. Opportunities to improve opioid use disorder and infectious disease services: Integrating responses to a dual epidemic. Washington, DC: The National Academies Press.
Naumann, R. B., C. P. Durrance, S. I. Ranapurwala, A. E. Austin, S. Proescholdbell, R. Childs, S. W. Marshall, S. Kansagra, and M. E. Shanahan. 2019. Impact of a community-based naloxone distribution program on opioid overdose death rates. Drug and Alcohol Dependence 204.
Neale, J., S. Vitoratou, E. Finch, P. Lennon, L. Mitcheson, D. Panebianco, D. Rose, J. Strang, T. Wykes, and J. Marsden. 2016. Development and validation of “SURE”: A patient reported outcome measure (PROM) for recovery from drug and alcohol dependence. Drug and Alcohol Dependence 165:159–167.
NIDA (National Institute on Drug Abuse). 2020. Overdose death rates. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates (accessed April 20, 2020).
Oquendo, M. A., and N. D. Volkow. 2018. Suicide: A silent contributor to opioid-overdose deaths. New England Journal of Medicine 378(17):1567–1569.
Padgett, D. K., V. Stanhope, B. F. Henwood, and A. Stefancic. 2011. Substance use outcomes among homeless clients with serious mental illness: Comparing housing first with treatment first programs. Community Mental Health Journal 47(2):227–232.
Peiper, N. C., S. D. Clarke, L. B. Vincent, D. Ciccarone, A. H. Kral, and J. E. Zibbell. 2019. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the southeastern United States. International Journal of Drug Policy 63:122–128.
Pike, E., M. Tillson, J. M. Webster, and M. Staton. 2019. A mixed-methods assessment of the impact of the opioid epidemic on first responder burnout. Drug and Alcohol Dependence 205:107620.
Platt, L., S. Minozzi, J. Reed, P. Vickerman, H. Hagan, C. French, A. Jordan, L. Degenhardt, V. Hope, and S. Hutchinson. 2017. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database of Systematic Reviews 9.
Rando, J., D. Broering, J. E. Olson, C. Marco, and S. B. Evans. 2015. Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. The American Journal of Emergency Medicine 33(9):1201–1204.
Roberts, N. P., P. A. Roberts, N. Jones, and J. I. Bisson. 2015. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: A systematic review and meta-analysis. Clinical Psychology Review 38:25–38.
Robinson, S. M., L. C. Sobell, M. B. Sobell, and G. I. Leo. 2014. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychology of Addictive Behaviors 28(1):154.
SAMHSA (Substance Abuse and Mental Health Services Administration). 2016. Facing addiction in America: The surgeon general’s report on alcohol, drugs, and health. https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf (accessed March 6, 2020).
SAMHSA. 2018. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. https://store.samhsa.gov/system/files/sma18-5054.pdf (accessed March 6, 2020).
Seth, P., L. Scholl, R. A. Rudd, and S. Bacon. 2018. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. Morbidity and Mortality Weekly Report 67(12):349.
Tobin, K., C. Clyde, M. Davey-Rothwell, and C. Latkin. 2018. Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. International Journal of Drug Policy 59:94–97.
Trump, D. J. 2019. Ending America’s opioid crisis. https://www.whitehouse.gov/opioids (accessed April 20, 2020).
Vilsaint, C. L., J. F. Kelly, B. G. Bergman, T. Groshkova, D. Best, and W. White. 2017. Development and validation of a brief assessment of recovery capital (BARC-10) for alcohol and drug use disorder. Drug and Alcohol Dependence 177:71–76.
Volkow, N. D., and C. Blanco. 2020. The changing opioid crisis: Development, challenges and opportunities. Molecular Psychiatry 1–16.
Wagner, K. D., R. W. Harding, R. Kelley, B. Labus, S. R. Verdugo, E. Copulsky, J. M. Bowles, M. L. Mittal, and P. J. Davidson. 2019. Post-overdose interventions triggered by calling 911: Centering the perspectives of people who use drugs (PWUDs). PLoS One 14(10):e0223823.
Walley, A. Y., Z. Xuan, H. H. Hackman, E. Quinn, M. Doe-Simkins, A. Sorensen-Alawad, S. Ruiz, and A. Ozonoff. 2013. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ 346:f174.
Wiercigroch, D., H. Sheikh, and J. Hulme. 2020. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Substance Abuse Treatment, Prevention, and Policy 15(1):1–10.
Williams, A. R., E. V. Nunes, A. Bisaga, F. R. Levin, and M. Olfson. 2019. Development of a cascade of care for responding to the opioid epidemic. The American Journal of Drug and Alcohol Abuse 45(1):1–10.
Willman, M. W., D. B. Liss, E. S. Schwarz, and M. E. Mullins. 2017. Do heroin overdose patients require observation after receiving naloxone? Clinical Toxicology 55(2):81–87.